Posts by: Joana Carvalho, MSc

Joana Carvalho, MSc

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that make up the lining of blood vessels — found in the umbilical cord of newborns.

August 1, 2019

Allergan Issues Worldwide Recall of Some Breast Implant Products Due to Lymphoma Risk

News

Allergan has issued a worldwide recall of its BIOCELL textured breast implant products, due to the potential risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The recall — for Allergan’s ... Read more

July 2, 2019July 2, 2019

CHMP Recommends Expanding Imbruvica Use in the EU to Include 2 New Cancer Regimens

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the expansion of the current marketing authorization for Imbruvica (ibrutinib) to ... Read more

June 27, 2019June 27, 2019

Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show

News

Copiktra (duvesilib) shows promising clinical activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), inducing responses in 44% to 57% of patients included in Phase 1 trials. ... Read more

June 25, 2019

Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma

News

Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b ... Read more

June 13, 2019June 20, 2019

FDA Gives OK to Polivy plus Rituxan-Bendamustine Combo to Treat Advanced DLBCL

News

The U.S. Food and Drug Administration (FDA) has approved — with conditions — Genentech‘s Polivy (polatuzumab vedotin-piiq), used in combination with Rituxan (rituximab) and bendamustine (a chemotherapy), to treat adults with relapsed ... Read more

June 6, 2019

Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals

News

Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, ... Read more

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic ... Read more

April 4, 2019

TG Therapeutics’ Umbralisib Proves Safe, Effective for Previously Treated Marginal Zone Lymphoma

News

TG Therapeutics‘ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising efficacy and safety in patients with relapsed or refractory marginal zone lymphoma, reducing cancer volume in more than half ... Read more

March 29, 2019

UK’s NICE Recommends Adcetris as Second-line Treatment for Certain CTCL Patients

News

After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous ... Read more

February 25, 2019

Exposure to Glyphosate in Herbicides Increases Risk of Non-Hodgkin’s Lymphoma, Study Says

News

Exposure to glyphosate, a common broad-spectrum herbicide used worldwide, increases the risk of non-Hodgkin’s lymphoma (NHL) by 41 percent in humans, a study says. The study, “Exposure to Glyphosate-Based ... Read more

Pin It on Pinterest